A long-term study of the safety of rituxan in patients with rheumatoid arthritis after an inadequate response to previous Anti-TNF [tumour necrosis factor] therapy (SUNSTONE).

Trial Profile

A long-term study of the safety of rituxan in patients with rheumatoid arthritis after an inadequate response to previous Anti-TNF [tumour necrosis factor] therapy (SUNSTONE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms SUNSTONE
  • Sponsors Genentech
  • Most Recent Events

    • 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Dec 2012 Planned End Date added 1 Dec 2013 as reported by ClinicalTrials.gov record.
    • 12 Nov 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top